40172-65-4

中文名稱 NAPHTHO[1,2-D]THIAZOL-2-AMINE

英文名稱 2-AMINO-BETA-NAPHTHOTHIAZOLE

CAS 40172-65-4

EINECS 編號 254-822-1

分子式 C11H8N2S

MDL 編號 MFCD00051329

分子量 200.26

MOL 文件 40172-65-4.mol

更新日期 2026/05/25 13:08:20

40172-65-4 結(jié)構(gòu)式

基本信息物理化學(xué)性質(zhì) 安全數(shù)據(jù) 圖譜信息 NAPHTHO[1,2-D]THIAZOL-2-AMINE價(jià)格(試劑級) 常見問題列表

基本信息

中文別名

化合物SKA-31
萘并[1,2-D]噻唑-2-胺

英文別名

2-AMINO-BETA-NAPHTHOTHIAZOLE

所屬類別

化學(xué)試劑：多環(huán)化合物

物理化學(xué)性質(zhì)

熔點(diǎn)184-188°C

沸點(diǎn)417.1±28.0 °C(Predicted)

密度1.403±0.06 g/cm3(Predicted)

儲存條件Keep in dark place,Sealed in dry,2-8°C

溶解度二甲基亞砜：≥30mg/mL

酸度系數(shù)(pKa)3.50±0.30(Predicted)

形態(tài)固體

顏色米白色

穩(wěn)定性Stable for 1 year as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months.

InChI1S/C11H8N2S/c12-11-13-10-8-4-2-1-3-7(8)5-6-9(10)14-11/h1-6H,(H2,12,13)

InChIKeyFECQXVPRUCCUIL-UHFFFAOYSA-N

SMILESNc1nc2c(ccc3ccccc23)s1

CAS 數(shù)據(jù)庫40172-65-4(CAS DataBase Reference)

EPA化學(xué)物質(zhì)信息Naphtho[1,2-d]thiazol-2-amine (40172-65-4)

安全數(shù)據(jù)

危險(xiǎn)性符號(GHS) 有害 (GHS07)

GHS07

警示詞警告

危險(xiǎn)性描述H302-H319

防范說明P264-P270-P280-P301+P312-P305+P351+P338-P337+P313

危險(xiǎn)品標(biāo)志Xn

危險(xiǎn)類別碼20/21/22-36/37/38-36-22

危險(xiǎn)類別碼R20/21/22-R36/37/38

安全說明22-36/37/39-26

安全說明S22-S36/37/39

WGK GermanyWGK 3

TSCATSCA listed

存儲類別11 - Combustible Solids

危險(xiǎn)性類別Acute Tox. 4 Oral
Eye Irrit. 2

圖譜信息

NAPHTHO[1,2-D]THIAZOL-2-AMINE(40172-65-4)核磁圖(¹HNMR)
NAPHTHO[1,2-D]THIAZOL-2-AMINE(40172-65-4)紅外圖譜(IR1)
NAPHTHO[1,2-D]THIAZOL-2-AMINE(40172-65-4)紅外圖譜(IR2)

NAPHTHO[1,2-D]THIAZOL-2-AMINE價(jià)格(試劑級)

報(bào)價(jià)日期	產(chǎn)品編號	產(chǎn)品名稱	CAS號	包裝	價(jià)格
2026/06/05	HY-111655R	NAPHTHO[1,2-D]THIAZOL-2-AMINE SKA-31 (Standard)	40172-65-4	5 mg	1500元
2026/06/05	HY-111655R	NAPHTHO[1,2-D]THIAZOL-2-AMINE SKA-31 (Standard)	40172-65-4	10 mg	2250元
2026/06/05	HY-111655	NAPHTHO[1,2-D]THIAZOL-2-AMINE SKA-31	40172-65-4	5mg	360元

常見問題列表

生物活性

SKA-31 是鉀離子通道 (potassium channel) 激活劑，作用于 KCa3.1，KCa2.2，KCa2.1 和 KCa2.3 的 EC50 值分別為 260 nM，1.9 μM，2.9 μM，2.9 μM，能增強(qiáng)內(nèi)皮源性超極化因子反應(yīng)，降低血壓。

靶點(diǎn)

EC50: 2.9 μM (KCa2.1), 1.9 μM (KCa2.2), 2.9 μM (KCa2.3), 260 nM (KCa3.1)

體外研究

SKA-31 activates KCa2/3 channels more potently than PK 26124, and is more selective over other Ion channels.
SKA-31 reduces cell viability with IC _50s of 5.3 μM , 46.9 μM in HCT-116 cells and HCT-8 cells, respectively.
SKA-31 (5.3 μM; 0-96 hours) reduces HCT-116 cells proliferation when added at time zero at 5.3 μM.
SKA-31 triggers apoptosis in HCT-116 cells at 5 μM, and the effect is smaller in HCT-8 cells at 45 μM.
SKA-31 increases the percentage of cells in G0/G1 phase in HCT-116 and HCT-8 cell lines at 5 μM and 45 μM, respectively.
SKA-31 further activates Caspase 3 and reduces Akt phosphorylation induced by CDDP.
SKA-31 has a synergic effect with CDDP also on the inhibition of HCT-116 cell proliferation.

Cell Viability Assay

Cell Line:	HCT-116 cells, HCT-8 cells
Concentration:
Incubation Time:	24?hours
Result:	Reduced cell viability with IC _50s of 5.3 μM , 46.9 μM in HCT-116 and HCT-8, respectively.

Cell Proliferation Assay

Cell Line:	HCT-116 cells
Concentration:	5.3 μM
Incubation Time:	0-96 hours
Result:	Reduced HCT-116 cells proliferation when added at time zero at IC _50S value.

Apoptosis Analysis

Cell Line:	HCT-116 cells, HCT-8 cells
Concentration:	5 μM (HCT-116 cells), 45 μM (HCT-8 cells)
Incubation Time:	24?hours
Result:	Triggered apoptosis in HCT-116 cells, and the effect was smaller in HCT-8 cells.

Cell Cycle Analysis

Cell Line:	HCT-116 cells, HCT-8 cells
Concentration:	5 μM (HCT-116), 45 μM (HCT-8)
Incubation Time:	24?hours
Result:	Increased the percentage of cells in G0/G1 phase in HCT-116 and HCT-8 cell lines.

Western Blot Analysis

Cell Line:	HCT-116 cells
Concentration:
Incubation Time:	24?hours
Result:	Further activated Caspase 3 and reduced Akt phosphorylation when co-treatment with CDDP in HCT-116 cells.

體內(nèi)研究

SKA-31 is not acutely toxic and has good pharmacokinetic properties.
SKA-31 potentiates native KCa3.1 and KCa2.3 in murine carotid endothelium with EC ₅₀ values of 225 nM and 1.6 μM for KCa3.1 and KCa2.3, respectively.
SKA-31 stimulates KCa3.1 and KCa2.3 in vascular endothelial cells and increases acetylcholine-induced endothelium-derived hyperpolarizing factor (EDHF) -mediated vasodilation.
SKA-31 potentiates EDHF-type vasodilations and lowers blood pressure in mice. Injections of SKA-31 (1-30 mg/kg; i.p.) lower MAP over 24 hours in normotensive wild-type mice but not in KCa3.1(-/-) mice (-/-).

Animal Model:	16-25 weeks mice
Dosage:	1 mg/kg, 10 mg/kg, and 30 mg/kg
Administration:	Intraperitoneal injection
Result:	Lower MAP over 24 hours in normotensive wild-type mice but not in KCa3.1(-/-) mice (-/-).